Pages that link to "Q43783873"

The following pages link to Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice (Q43783873):

Displaying 48 items.

• The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of Adipogenesis (Q28078585) (← links)
• A subset of osteoblasts expressing high endogenous levels of PPARgamma switches fate to adipocytes in the rat calvaria cell culture model (Q33644501) (← links)
• What's the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health (Q33726338) (← links)
• Altered metabolism and lipodystrophy in the early B-cell factor 1-deficient mouse (Q33772356) (← links)
• Increased marrow adiposity in premenopausal women with idiopathic osteoporosis (Q34281779) (← links)
• Marrow fat and bone--new perspectives (Q34326863) (← links)
• Expansion of Bone Marrow Adipose Tissue During Caloric Restriction Is Associated With Increased Circulating Glucocorticoids and Not With Hypoleptinemia. (Q34506286) (← links)
• Effects of thiazolidinediones on bone loss and fracture (Q34701705) (← links)
• Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women (Q34750140) (← links)
• Thiazolidinedione use and bone loss in older diabetic adults (Q35023205) (← links)
• Effects of obesity on bone metabolism (Q35121884) (← links)
• Resolving the Two "Bony" Faces of PPAR-gamma. (Q35191573) (← links)
• Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis (Q35561066) (← links)
• Diabetes, TZDs, and Bone: A Review of the Clinical Evidence (Q35606042) (← links)
• Fine-Tuning Reception in the Bone: PPARgamma and Company. (Q35606046) (← links)
• Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. (Q35745608) (← links)
• Bone is a target for the antidiabetic compound rosiglitazone. (Q35758012) (← links)
• Bone and fat: old questions, new insights (Q35774928) (← links)
• Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. (Q36028610) (← links)
• Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. (Q36282399) (← links)
• Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators (Q36715753) (← links)
• Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. (Q36830195) (← links)
• Fat targets for skeletal health (Q36866334) (← links)
• Spinal and paraspinal lesions: the role of stereotactic body radiotherapy (Q36887077) (← links)
• Skeletal consequences of thiazolidinedione therapy (Q36954391) (← links)
• Marrow fat and the bone microenvironment: developmental, functional, and pathological implications (Q37172974) (← links)
• The role of the vertebral end plate in low back pain. (Q37371953) (← links)
• Thiazolidinediones and bone. (Q37430507) (← links)
• Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy. (Q37492497) (← links)
• Marrow adiposity assessed on transiliac crest biopsy samples correlates with noninvasive measurement of marrow adiposity by proton magnetic resonance spectroscopy ((1)H-MRS) at the spine but not the femur (Q37550976) (← links)
• Negative influence of a long-term high-fat diet on murine bone architecture (Q37631449) (← links)
• Intracellular delivery of cell-penetrating peptide-transcriptional factor fusion protein and its role in selective osteogenesis (Q37641466) (← links)
• Bone marrow adipose tissue: formation, function and regulation. (Q37701441) (← links)
• Adipocytic cells augment the support of primitive hematopoietic cells in vitro but have no effect in the bone marrow niche under homeostatic conditions (Q37718855) (← links)
• Adipocytes and the regulation of bone remodeling: a balancing act. (Q38150258) (← links)
• An update of human mesenchymal stem cell biology and their clinical uses. (Q38201302) (← links)
• The role of CCAAT/enhancer binding protein (C/EBP)-alpha in osteogenesis of C3H10T1/2 cells induced by BMP-2. (Q38357733) (← links)
• Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future (Q38641190) (← links)
• Arsenic trioxide promotes senescence and regulates the balance of adipogenic and osteogenic differentiation in human mesenchymal stem cells (Q42755677) (← links)
• Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus (Q43153261) (← links)
• The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate (Q46807429) (← links)
• Fat fraction mapping using magnetic resonance imaging: insight into pathophysiology. (Q47875690) (← links)
• Differential effects of bisphenol A diglicydyl ether on bone quality and marrow adiposity in ovary-intact and ovariectomized rats (Q47976343) (← links)
• Metabolic Coupling Between Bone Marrow Adipose Tissue and Hematopoiesis (Q51746127) (← links)
• Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar (Q51757343) (← links)
• The Unique Metabolic Characteristics of Bone Marrow Adipose Tissue (Q64244082) (← links)
• Diabetes Mellitus-induced Bone Fragility. (Q64936056) (← links)
• Reporting Guidelines, Review of Methodological Standards, and Challenges Toward Harmonization in Bone Marrow Adiposity Research. Report of the Methodologies Working Group of the International Bone Marrow Adiposity Society (Q90379794) (← links)